文献速递药物相互作用药物不良反应与药物警戒

ACEI与胰岛素促泌剂联用及严重低血糖风险

Angiotensin-Converting Enzyme Inhibitors Used Concomitantly with Insulin Secretagogues and the Risk of Serious Hypoglycemia.
PubMed 文献 · Clin Pharmacol Ther · 2021-08-23

本研究采用自身对照病例系列设计,利用美国5州Medicaid与Medicare链接数据(1999-2011年),评估接受胰岛素促泌剂的患者中联用ACEI与严重低血糖住院/急诊就诊的关联。结果显示,除格列美脲(RR 1.23;95%CI 1.11-1.37)外,其他促泌剂及二甲双胍联用ACEI均未见严重低血糖风险显著升高。

要点

  • 联用ACEI与格列美脲者严重低血糖风险轻度升高(RR 1.23;95%CI 1.11-1.37)。
  • 联用ACEI与格列吡嗪、格列本脲、瑞格列奈或二甲双胍未观察到风险显著升高。
  • 那格列奈联用ACEI显示风险轻度降低(RR 0.73;95%CI 0.56-0.96)。

核心结论

  • 总体而言,ACEI与胰岛素促泌剂联用未显示与严重低血糖发生率升高相关,但格列美脲可能例外。

研究设计与样本

  • 自身对照病例系列设计,使用美国5州1999-2011年Medicaid索赔数据链接Medicare索赔数据。
  • 暴露为胰岛素促泌剂或二甲双胍(阴性对照)治疗期间ACEI的活跃处方。
  • 结局为因严重低血糖住院或急诊就诊,通过出院诊断代码识别(阳性预测值约78-89%)。
  • 采用条件Poisson回归计算混杂因素校正后的率比(RR)及95%置信区间(CI)。

主要发现

  • 格列吡嗪联用ACEI的RR为1.06(95%CI 0.98-1.15),无统计学升高。
  • 格列本脲联用ACEI的RR为1.05(95%CI 0.96-1.15),无统计学升高。
  • 瑞格列奈联用ACEI的RR为1.15(95%CI 0.94-1.41),无统计学升高。
  • 二甲双胍联用ACEI的RR为1.02(95%CI 0.97-1.06),无统计学升高。
  • 格列美脲联用ACEI的RR为1.23(95%CI 1.11-1.37),轻度升高;那格列奈联用ACEI的RR为0.73(95%CI 0.56-0.96),轻度降低。

临床怎么用

  • 临床使用格列美脲时应警惕与ACEI联用可能轻度增加严重低血糖风险,需加强血糖监测。
  • 联用ACEI与其他胰岛素促泌剂(如格列吡嗪、格列本脲、瑞格列奈)或二甲双胍时,严重低血糖风险未见显著升高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Serious hypoglycemia is a major adverse event associated with insulin secretagogues. Previous studies have suggested a potential relationship between angiotensin-converting enzyme inhibitors (ACEIs) used with sulfonylureas and serious hypoglycemia, and widely used drug compendia warn of this potential drug-drug interaction. We investigated the association between serious hypoglycemia and concomitant use of ACEIs in patients receiving insulin secretagogues, using the self-controlled case series design and Medicaid claims data from 5 US states linked to Medicare claims from 1999-2011. The exposure of interest was active prescription for ACEIs during insulin secretagogue or metformin (negative control object drug) episodes. The outcome was hospital presentation for serious hypoglycemia, identified by discharge diagnosis codes in inpatient and emergency department claims (positive predictive value ~ 78-89%). We calculated confounder-adjusted rate ratios (RRs) and 95% confidence internals (CIs) of outcome occurrence during ACEI-exposed vs. ACEI-unexposed time using conditional Poisson regression. The RRs for ACEIs were not statistically elevated during observation time of glipizide (RR, 1.06; CI, 0.98-1.15), glyburide (RR, 1.05; CI, 0.96-1.15), repaglinide (RR, 1.15; CI, 0.94-1.41), or metformin (RR, 1.02; CI, 0.97-1.06); but was modestly elevated with glimepiride (RR, 1.23; CI, 1.11-1.37) and modestly reduced with nateglinide (RR, 0.73; CI, 0.56-0.96). The overall pattern of results do not suggest that ACEIs used with insulin secretagogues were associated with increased rates of serious hypoglycemia, with the possible exception of glimepiride.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Hee Nam Y, Brensinger CM, Bilker WB, et al. Angiotensin-Converting Enzyme Inhibitors Used Concomitantly with Insulin Secretagogues and the Risk of Serious Hypoglycemia. Clin Pharmacol Ther. 2021. PMID: 34312836. doi:10.1002/cpt.2377

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。